Development Pipeline

pexidartinib

CSF-1R
TGCT/PVNS/GCT-TS1
   

pexidartinib + eribulin

CSF-1R, KIT
Metastatic Breast Cancer
   

pexidartinib + paclitaxel

CSF-1R, KIT
Advanced Ovarian Cancer
   

pexidartinib + pembrolizumab

CSF-1R
Solid Tumors
   

pexidartinib + durvalumab

CSF-1R
Colorectal, Pancreas Cancer
   

pexidartinib (China, UK)

KIT
KIT-Mutant Melanoma
   

pexidartinib

CSF-1R
Pediatric Neurofibromatosis Type 1
   

pexidartinib + sirolimus

CSF-1R
Malignant Peripheral Nerve Sheath Tumors
   

pexidartinib + RT +ADT

CSF-1R
Prostate Cancer
   
Compound
Relevant Target
Targeted Cancer Indication

PLX7486

TRK, CSF-1R
Solid Tumors
   

PLX9486

KIT-Mutant
Gastrointestinal Stromal Tumor, KIT-Mutant Tumors
   

PLX8394

BRAF
BRAF-Mutant Tumors
   

PLX51107

BET
Solid Tumors, Hematologic Malignancies
   

PLX73086

CSF-1R
Solid Tumors
   

1 Clinical proof of concept achieved in Phase 1.